4.0 Article

Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons

Journal

HEMODIALYSIS INTERNATIONAL
Volume 21, Issue 3, Pages 393-408

Publisher

WILEY
DOI: 10.1111/hdi.12503

Keywords

Anemia; calcium; hemodialysis; parathyroid hormone; phosphate; practice patterns

Funding

  1. Amgen
  2. Kyowa Hakko Kirin
  3. AbbVie
  4. Sanofi Renal
  5. Baxter Healthcare
  6. Vifor Fresenius Medical Care Renal Pharma
  7. Keryx Biopharmaceuticals
  8. Merck Sharp Dohme
  9. Proteon Therapeutics
  10. Relypsa
  11. F. Hoffmann-LaRoche
  12. BHC Medical
  13. Janssen
  14. Takeda
  15. Kidney Foundation of Canada
  16. Hexal
  17. DGfN
  18. Shire
  19. WiNe Institute
  20. Japanese Society for Peritoneal Dialysis (JSPD)

Ask authors/readers for more resources

Introduction: There is little comparable information about hemodialysis (HD) practices in low- and middle income countries, including Russia. Evaluation of HD in Russia and its international comparisons could highlight factors providing opportunities for improvement. Methods: We examined treatment patterns for 481 prevalent HD patients in 20 Russian facilities, and compared them to contemporary data for 8512 patients from 311 facilities in seven European countries, Japan, and North America. Data were collected according to the uniform methodology of the Dialysis Outcomes and Practice Patterns Study, phase 5. Findings: Compared to other regions, Russian patients were younger (mean age 53.4 years), had a lower percent of males (52.5%), higher arteriovenous fistula use (89.7%), and longer treatment time (mean: 252 minutes, SD: 37 minutes). Mean single pool Kt/V was 1.49 (SD 0.58). Prescription of dialysate calcium 3.5 mEq/L and aluminum-based phosphate binders were high (15.2% and 17.6% of patients, respectively), while intravenous vitamin D and cinacalcet were low (3.3% and 2.2%, respectively). The percents with parathyroid hormone >600 pg/mL (30.9%) and serum phosphate >1.78 mmol/L (37.7%) were high. Use of erythropoetin stimulating agents (78%) was lower, but hemoglobin, ferritin, and transferrin saturation were generally comparable to North America and Europe. Discussion: These detailed data for hemodialysis in Russia demonstrate that many practice patterns contrasted sharply to those in Europe, Japan, and North America, while other features were similar. Our analysis revealed several positive and some less favorable treatment patterns in Russia that represent opportunities for improving patient care and outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available